IRIS – Institutional Research Information System
IRIS è il sistema di gestione della ricerca dell’Università degli Studi di Milano-Bicocca.Il repository BOA è il modulo del sistema dedicato alla raccolta e alla disseminazione della produzione scientifica di Ateneo. Le pubblicazioni sono ricercabili per parola chiave attraverso il box nella barra orizzontale in alto oppure, mediante il pulsante Sfoglia, per "Afferenza", "Autore", "Titolo", "Tipologia" o "Settore scientifico-disciplinare".
IRIS contiene inoltre alcuni moduli dedicati alla registrazione dei progetti e dei contratti, e alla reportistica avanzata per le attività di valutazione della ricerca
EnglishPurpose To investigate the feasibility of perfusion-CT (p-CT) measurements in quantitative assessment of hemodynamic changes related to sorafenib in patients with advanced hepatocellular carcinoma (HCC). Materials and methods Twenty-two patients with advanced HCC underwent p-CT study (256-MDCT scanner) before and 2 months after sorafenib administration. Dedicated perfusion software generated a quantitative map of arterial and portal perfusion and calculated the following perfusion parameters in target liver lesion: hepatic perfusion (HP), time-to-peak (TTP), blood volume (BV), arterial perfusion (AP), and hepatic perfusion index (HPI). After the follow-up scan, patients were categorized as responders and non-responders, according to mRECIST. Perfusion values were analyzed and compared in HCC lesions and in the cirrhotic parenchyma (n = 22), such as between baseline and follow-up in progressors and non-progressors. Results Before treatment, all mean perfusion values were significantly higher in HCC lesions than in the cirrhotic parenchyma (HP 47.8 ± 17.2 vs 13.3 ± 6.3 mL/s per 100 g; AP 47.9 ± 18.1 vs 12.9 ± 10.7 mL/s; p < 0.001). The group that responded to sorafenib (n = 17) showed a significant reduction of values in HCC target lesions after therapy (HP 29.2 ± 23.3 vs 48.1 ± 15.1; AP 29.4 ± 24.6 vs 49.2 ± 17.4; p < 0.01), in comparison with the non-responder group (n = 5) that demonstrated no significant variation before and after treatment of HP (46.9 ± 25.1 vs 46.7 ± 24.1) and AP (43.4 ± 21.7 vs 43.5 ± 24.6). Among the responder group, HP percentage variation (Δ) in target lesions, during treatment, showed a significantly different (p = 0.04) ΔHP in the group with complete response (79%) compared to the group with partial response or stable disease (16%). Conclusions p-CT technique can be used for HCC quantitative assessment of changes related to anti-angiogenic therapy. Identification of response predictors might help clinicians in selection of patients who may benefit from targeted-therapy allowing for optimization of individualized treatment.
| Citazione: | Ippolito, D., Querques, G., Okolicsanyi, S., Franzesi, C., Strazzabosco, M., & Sironi, S. (2017). Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. EUROPEAN JOURNAL OF RADIOLOGY, 90, 34-41. |
| Tipo: | Articolo in rivista - Articolo scientifico |
| Carattere della pubblicazione: | Scientifica |
| Presenza di un coautore afferente ad Istituzioni straniere: | Si |
| Titolo: | Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study |
| Autori: | Ippolito, D; Querques, G; Okolicsanyi, S; Franzesi, C; Strazzabosco, M; Sironi, S |
| Autori: | IPPOLITO, DAVIDE (Primo) QUERQUES, GIULIA (Secondo) STRAZZABOSCO, MARIO (Penultimo) SIRONI, SANDRO (Ultimo) |
| Data di pubblicazione: | 2017 |
| Lingua: | English |
| Rivista: | EUROPEAN JOURNAL OF RADIOLOGY |
| Digital Object Identifier (DOI): | 10.1016/j.ejrad.2017.02.027 |
| Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
Copyright © 2018